Study of biology in people with BRAF V600E metastatic colon cancer
Part of Cancer, Digestive system clinical trials.
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have metastatic colorectal cancer confirmed as “BRAF V600E” (tested on tumor tissue)
- Have tumor tissue available from before starting this study (a needle sample only is usually not enough)
- Know your tumor “MMR/microsatellite” result (or are currently getting it tested)
- Be able and willing to sign consent and follow study procedures
- Have support/coverage through the local social security system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment for people whose colorectal cancer has spread and cannot be removed by surgery, and who have a specific gene change called BRAFV600E. It aims to find out if the treatment can help shrink or control the cancer.
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
This trial is researching colorectal cancer that has a specific genetic change called BRAF V600E. It uses advanced testing (multi-omics) to learn more about the cancer and find better ways to treat it.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.